Please assess the completion status of the following clinical trial:

Trial Title: Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy 40 to 44-months-old children, who participated and completed the study V72P6 (NCT00381615; follow-on subjects)~* Healthy 40 to 44-months or 60 to 62-months-old children (naïve subjects)~Exclusion Criteria:~* Previous ascertained or suspected disease caused by N. meningitidis~* History of severe allergic reaction after previous vaccinations or hypersensitivity to any vaccine component~* Any serious chronic or progressive disease~* Known or suspected impairment/alteration of the immune system~* Receipt of, or intent to immunize with another vaccine, within 30 days prior and after vaccination with the investigational vaccines (within 14 days for licensed flu vaccines)

- Gender: ALL
- Minimum Age: 40 Months
- Maximum Age: 62 Months
- Healthy Volunteers: t

Study Arms:
- 5rMenB (Type: EXPERIMENTAL): Subjects who had received four doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV) (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of the same vaccine, at 40 months of age in the present study.
- 5rMenB+OMV NZ (Type: EXPERIMENTAL): Subjects who had received four doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of the same vaccine, at 40 months of age in the present study.
- 3rMenB (Type: EXPERIMENTAL): Subjects who had previously received one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine without OMV (at 12 months of age) were administered two doses of the same vaccine, at 40 and 42 months of age in the present study.
- 3rMenB+OMV NZ (Type: EXPERIMENTAL): Subjects who had previously received one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine (at 12 months of age) were administered two doses of the same vaccine, at 40 and 42 months of age in the present study.
- Naive_4042 (Type: EXPERIMENTAL): Vaccine-naive subjects who received two catch-up doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 40 and 42 months of age in the present study.
- Naive_6062 (Type: EXPERIMENTAL): Vaccine-naive subjects who received two catch-up doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 60 and 62 months of age in the present study.

Based on this trial design, predict the completion outcome and termination type (if applicable).